<h3>Title</h3>
<p><span style="color: #0000ff;">PROTACs (Proteolysis Targeting Chimeras) and Oligo-PROTACs: Emerging strategies to confront diseases</span></p>
<p><strong><span style="text-decoration: underline;">Abstract</span> :</strong></p>
<p>PROTACs are emerging class of drug molecules which have two desperate domains connected by a linker molecule, one binds to protein of interest (POI) whereas another attach to E3-ligase. The formed ternary complex (POI-PROTAC-E3 ligase) then harnesses cell’s ubiquitin proteasomal system (UPS) for degradation of POI via it’s polyubiquitination. Recently, we and others are applied the concept of small molecular-based PROTAC to oligonucleotide-based PROTAC (oligo-PROTAC) to target previously un-targetable but highly desirable protein targets such as transcription factors or for numerous other practical applications in biology.</p>
<p> <img style="display: block; margin-left: auto; margin-right: auto;" src="images/Karan.jpg" alt="" width="709" height="377" /></p>
<p> </p>
<p>I will discuss few of the newly discovered PROTACs, oligo-PROTACs and our findings in G4-PROTAC (G-quadruplex-PROTACs) for their specific aims. Additionally, the proposed novel oligo based PROTAC entities for my planned research work.</p>